survival rate is 63% in the USA. 3 Surgery is the most established modality for initial definitive treatment of oral cancer. However, extended surgery for patients with locally advanced oral squamous cell carcinoma might result in the loss of oral function, including dysphagia, dysarthria and masticatory disturbance. Therefore, more effective treatment with fewer complications for oral cancer needs to be developed.
It is well known that rheumatoid arthritis patients taking aspirin, a COX inhibitor, for a long time have a lower incidence of colorectal cancer. 4 We previously reviewed that inhibition of COX-2 has anticancer effects on colorectal cancer, lung cancer, cervical cancer, breast cancer, prostate cancer and esophageal cancer. 5 COX-2 produces prostaglandin E 2 (PGE 2 ). PGE 2 is one of the major products generated by the actions of COX on arachidonic acid. It has been established that PGE 2 is an important mediator of fever, pain and inflammation. PGE 2 functions mainly through G protein-coupled PGE receptors designated EP1, EP2, EP3 and EP4. 6 The EP4 receptor is one of four receptor subtypes for PGE 2 .
Stimulation of EP4 receptors usually increases intracellular cyclic AMP (cAMP) levels and activates protein kinase A (PKA) through stimulatory G protein (Gs). 6 We previously reviewed that PGE 2 and EP4 regulate cell migration or metastasis of colorectal cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer and renal cancer. 5 However, little information is available regarding the function and cellular signaling pathway of EP4 per se, including migration in oral cancer. In cellular signaling of migration/metastasis, previous reports showed that EP4 mediated cell migration/metastasis through PBK/Akt (protein kinase B), cAMP, ERK or β-arrestin 1 in lung cancer, breast cancer and renal cancer. 5 In contrast, there are few reports on the relationships between EP4 and Ca 2+ signaling in human eosinophil and mouse neuroblastoma (Neuro-2a) cells. 7, 8 Therefore, despite intracellu- 
| Cell viability assay
Cell proliferation assays were carried out with a commercial Cell Proliferation Assay Kit (ATCC) using XTT. were carried out as previously described.
13,21
| Reverse transcriptase-polymerase chain reaction
Isolation of total RNA, generation of cDNA and RT-PCR analysis were carried out as previously described. 22, 23 Sequences of the specific primers were as follows: EP4 (forward, 5′-CCGGC GGTGATGTTCATCTT-3′; reverse, 5′-CCCACATACCAGCGTGTA GAA-3′), MMP-2 (forward, 5′-CGACCACAGCCAACTACGAT-3′;
reverse, 5′-GTCAGGAGAGGCCCCATAGA-3′), MMP-9 (forward, 5′-TGTACCGCTATGGTTACACTCG-3′; reverse, 5′-GGCAGGGACA GTTGCTTCT-3′) and GAPDH (forward, 5′-CCCATCACCATCTT CCAGGAGCG-3′; reverse, 5′-GGCAGGGATGATGTTCTGGAGAGCC-3′).
| Western blotting
Western blot analyses were carried out as previously described.
19,20
The following primary antibodies were used for immunoblot- 
| Scratch assay
Scratch assay analyses were carried out as previously described.
13
Bright-field images were captured (Eclipse Ti; Nikon Corporation) and analyzed.
| Lung colonization assay
HSC-3 cells transfected with a scramble control shRNA or EP4
shRNA (EP4 shRNA-1 and EP4 shRAN-2) lentivirus were harvested and injected (2 × 10 6 cells/0.2 mL) into the tail veins of Balb/c Slc-nu/ nu mice (female, 4-5 weeks old, 4 mice/group) (SLC). 13, 24 Five weeks after the injection of the cells, metastatic colonies on the surfaces of the lungs were fixed with formalin and counted under a dissection microscope.
| Fluorescence imaging of intracellular Ca

2+
Measurement of intracellular Ca 2+ concentration was done as previously described with some modifications. 
| Immunoprecipitation
Cells were grown to 90% confluence on 6-cm dishes, washed with PBS, lysed and protein was recovered by sonication with RIPA buffer (Thermo Scientific). Dynabeads-protein G for immunoprecipitation were separated by a magnet, and after repeated washing four times, F I G U R E 2 EP4 regulated the migration of oral cancer cells. A, Western blot analysis showed that EP4 was significantly reduced by shRNA transduction with lentivirus in HSC-3 (EP4 shRNA-1 and EP4 shRNA-2). Representative pictures and quantification of the scratch assay. B, The moving area was decreased by the ablation of EP4 in HSC-3 (**P < .01, ***P < .001, n = 4) F I G U R E 3 EP4 regulates metastasis of oral cancer. A, HSC-3, oral cancer cells with knockdown of EP4 were injected into the tail vein of Balb/c nu/nu mice. Five weeks later, the lungs were removed and fixed with formalin. Representative computed tomography (CT) images of mouse lungs are shown (control shRNA, EP4 shRNA-1 and EP4 shRNA-2). B, Representative images of metastatic colonies in the lung are shown (control shRNA, EP4 shRNA-1 and EP4 shRNA-2) (left) (***P < .001, n = 4). The number of metastatic colonies on the lung surface was counted under a dissection microscope (right). C, Lung weights of mice are shown (**P < .01, n = 4). D, Representative pictures of HE staining (control shRNA, EP4 shRNA-1 and EP4 shRNA-2) the isolated protein complexes were subjected to western blotting with the respective antibodies.
| Gelatin zymography
HSC-3 was stimulated with each reagent for 24 hours. Gelatin zymography was carried out using culture supernatant from HSC-3 cells.
27,28
| Ethics statement
Animal experiments were carried out according to Yokohama City University guidelines for experimental animals. All experimental protocols were approved by the Animal Care and Use Committee at Yokohama City University, School of Medicine.
| Data analysis and statistics
Statistical comparisons among groups were carried out using
Student's t test, one-factor analysis of variance (ANOVA) or twoway ANOVA with the Bonferroni post-hoc test. Statistical significance was set as P < .05. Significant differences are indicated by *P < .05; **P < .01; and ***P < .001; ns, not significant.
| RE SULTS
| EP4 was expressed and involved in cell migration in human oral cancer cells
It was reported that expression levels of both COX and PGE 2 are elevated in cancer patients. 29 Figure 1A ).
EP4 regulates cell migration in colorectal cancer, lung cancer, breast cancer, ovarian cancer and renal cancer. [32] [33] [34] [35] [36] We next examined the role of EP4 in human oral cancer cell migration.
ONO-AE3-208, an EP4 antagonist, negated PGE 2 -induced cell migration ( Figure 1B ). In contrast, ONO-AE1-437, an EP4 agonist, promoted cell migration ( Figure 1C ). In our experiment, we confirmed that the optimal concentration of ONO-AE1-437 was 1 µmol/L. We also confirmed that the reagents used in the scratch assay did not affect cell proliferation by themselves ( Figure S1A ).
| EP4 knockdown suppressed cell migration in human oral cancer cells
When EP4 was ablated by shRNA (Figure 2A ), migration was reduced in both EP4 shRNA-1 and EP4 shRNA-2 cells ( Figure 2B ). In contrast, proliferation was not reduced in EP4-knockdown oral cancer cells ( Figure S1B ). Furthermore, we explored the signaling pathway by which EP4 signaling promotes cell migration in HSC-3 cell lines.
Because several recent studies have shown that PGE 2 promotes cancer cell migration through the EP4-Akt pathway in lung cancer and renal cancer, we hypothesized that the PI3K signaling pathway may be involved in oral cancer. 33, 36 However, the PKA inhibitor PKI- 
| Inhibition of EP4 suppressed oral cancer cell metastasis in mice
We next examined whether ablation of EP4 reduced cell migration and thus metastasis to distant organs. HSC-3 cells with/without knockdown of EP4 were injected into the tail vein of Balb/c nu/nu mice.
Five weeks after injection, colonies in the lungs of mice were visualized by computed tomography (CT) ( Figure 3A ). CT images showed that the EP4-knockdown group had decreased numbers of metastatic colonies in the lungs of mice compared to the control group. When the lungs were removed and fixed with formalin, the EP4-knockdown group showed decreased numbers of metastatic colonies on the surface of the mouse lung ( Figure 3B ). Furthermore, lung weights in the control group were heavier than those in the EP4-knockdown group F I G U R E 4 EP4 signal induced intracellular calcium elevation in oral cancer cells. A, The EP4 agonist significantly induced intracellular calcium elevation in HSC-3 cells (***P < .001, n = 4). B, EP4 agonist-induced intracellular calcium elevation was reduced by EP4 knockdown (EP4 shRNA-1) (*P < .05, ns; no significant difference, n = 4). C, EP4 agonist-induced intracellular calcium elevation was reduced by EP4 knockdown (EP4 shRNA-2) (***P < .001, n = 4). D, Absence of extracellular calcium (calcium-free HEPES buffer) negated EP4 agonist-induced intracellular calcium elevation (**P < .01, n = 4). E, Inositol-1,4,5-trisphosphate (IP 3 ) receptor inhibitor (Xestospongin C) did not negate EP4 agonist-induced intracellular calcium elevation (*P < .05, ***P < .001, n = 4). F, Store-operated Ca 2+ entry (SOCE) inhibitor (YM58483) negated EP4 agonist-induced intracellular calcium elevation (**P < .01, n = 4). G, PI3K inhibitor (LY294002) negated EP4 agonist-induced intracellular calcium elevation, not protein kinase (PK)A inhibitor (PKI-(14-22)-amide) (**P < .01, n = 4). H, MEK inhibitor (U0126) did not negate EP4 agonist-induced intracellular calcium elevation (*P < .05, **P < .01, n = 4)
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OSAWA et Al ( Figure 3C ). Similar findings were found in pathological specimens. The nodules indicated lung metastasis. The cells were round and polygonal with clear cytoplasm. Nuclei were enlarged and oval ( Figure 3D ).
These data suggest that inhibition of endogenous EP4 suppresses oral cancer cell migration by reducing lung metastasis. , a ubiquitous second messenger, regulates diverse cellular functions, including cell migration. 37 We previously reported that SOCE, which is a major mechanism of import from the extracellular to the intracellular space, contributes to melanoma progression. 13 As mentioned earlier, in the current study, we confirmed that EP4 is associated with migration/metastasis in oral cancer in vitro and in vivo; therefore, we focused on EP4 and Ca 2+ signaling. We first examined whether EP4 is involved in the regulation of intracellular Ca
| EP4 signaling induced
2+
.
We confirmed that the EP4 agonist notably increased intracellular entry, not from the ER. In addition, the PI3K inhibitor LY294002 suppressed EP4-induced Ca 2+ influx ( Figure 4G ). In contrast, the PKA inhibitor PKI-(14-22)-amide did not negate the EP4 agonist-induced Ca 2+ elevation ( Figure 4G) . Similarly, the MEK inhibitor U0126 did not negate the EP4-induced Ca 2+ influx, suggesting that Ca 2+ signaling is located upstream of MEK ( Figure 4H ). Taken together, these data suggest that EP4 signaling mediates Ca 2+ influx from the extracellular space through the PI3K pathway, not the PKA pathway. Figure 5A ). We confirmed that cell proliferation was not reduced in either Orai1 or STIM1-knockdown oral cancer cells ( Figure S1B ). As mentioned earlier, it has been reported that Orai1 is the SOCE component; therefore, we examined the interaction of EP4 and Orai1 in HSC-3. 11 Immunoprecipitation showed that EP4
| EP4 interacted with Orai1 and increased intracellular calcium elevation
was colocalized and formed complexes with Orai1 ( Figure 5B ; Figure   S4 ). Surprisingly, EP4 also formed complexes with TRPC1 ( Figure   S5 ). In contrast, EP4 did not form a complex with STIM1 (data not shown). Taken together, our results indicated that EP4 colocalized and formed complexes with both Orai1 and TRPC1. As far as we know, this is the first report that EP4 was colocalized and forms complexes with Orai1 and TRPC1.
More importantly, when Orai1 was ablated by shRNA in HSC-3
( Figure 5C ), the EP4 agonist did not promote cell migration and failed to induce Ca 2+ influx (Figure 5D ,E; Figure S6 ). In contrast, when STIM1 was also ablated by shRNA in HSC-3 ( Figure 5C ), the EP4 agonist induced Ca 2+ influx ( Figure 5F ). Taken together, these results suggested that Orai1 was necessary for EP4 to induce Ca 2+ influx from the extracellular space and that Orai1 worked without the interaction of STIM1.
| EP4 signaling phosphorylated ERK through the PI3K pathway
We previously reported that SOCE regulates melanoma cell migration by ERK phosphorylation. 13 Ca 2+ elevation positively regulates small GTPase Ras signaling, leading to increased ERK phosphorylation. 38 Because ERK is a regulator of cell motility, we hypothesized that the MEK/ERK pathway may be involved in EP4 agonist-induced cell migration. 39 Indeed, the EP4 agonist mostly phosphorylated ERK 6 hours after stimulation ( Figure 6A ). However, PKI-(14-22)-amide did not negate the EP4 agonist-induced phosphorylation of ERK, yet LY294002 negated it, suggesting that EP4 phosphorylated ERK through the PI3K pathway and that PI3K is located upstream of ERK ( Figure 6B ). Furthermore, when Orai1 was ablated by shRNA in HSC-3, the EP4 agonist failed to phosphorylate ERK compared to the control ( Figure 6C,D) . These results suggested that Orai1 was necessary for EP4 agonist-induced ERK phosphorylation.
F I G U R E 5 EP4 was colocalized, forming complexes with Orai1 and inducing intracellular calcium elevation. A, Western blotting was carried out to confirm whether STIM1 and Orai1 were expressed in HSC-3 and OSC-19. B, Immunoprecipitation for EP4 and Orai1 was carried out. C, Western blot analysis showed that Orai1 or stromal interaction molecule 1 (STIM1) was significantly reduced by shRNA transduction with lentivirus in HSC-3 cells (Orai1 shRNA-1 and Orai1 shRNA-2, and STIM1 shRNA-1 and STIM1 shRNA-2). D, Representative pictures and quantification of the scratch assay. Scratch assays confirmed that EP4 agonist-induced cell migration was decreased by ablation of Orai1 in HSC-3 (***P < .001, ns; no significant difference, n = 4). E, EP4 agonist-induced intracellular calcium elevation was reduced by Orai1 knockdown (Orai1 shRNA-1 and Orai1 shRNA-2) (*P < .05, ***P < .001, ns; no significant difference, n = 4). F, EP4 agonist-induced intracellular calcium elevation was not reduced by STIM1 knockdown (STIM1 shRNA-1 and STIM1 shRNA-2) (*P < .05, **P < .01, n = 4)
We previously reported that ERK signaling can increase calpain activity in melanoma cells. 40 Calpain was found to be a Ca 2+ -dependent enzyme. 41 α-Spectrin is an important cytoskeletal protein that ensures vital cellular properties, including polarity and cell stabilization. α-Spectrin is cleaved by calpain, resulting in increasing proteolytic activities and enhancement of actin-binding capacities of spectrin. 42 Therefore, we next evaluated whether EP4
agonists activate calpain and α-spectrin. We confirmed that calpain and cleaved α-spectrin, a target enzyme of calpain, were increased by EP4 agonists in a time-dependent way ( Figure 6E ). These data suggested that EP4 signaling induced Ca 2+ influx and then activated calpain, resulting in increased cleavage of α-spectrin.
| EP4 signaling increased mRNA and activity of MMP-2 and MMP-9
Matrix metalloproteinase-2 and MMP-9 are elastolytic enzymes.
We recently found that CJ-42794, a selective EP4 antagonist, suppressed MMP-2 and MMP-9 activation in mouse abdominal aortic aneurysm (AAA) tissues in vivo. 28 MMP-2 and MM-9 are known enzymes that break the extracellular matrix. It is necessary to break the extracellular matrix around the tumor in migration and invasion of cancer cells. 43, 44 The ERK pathway is also associated with MMP-2 activation in oral cancer. 45, 46 Indeed, the EP4 agonist increased the mRNA of MMP-2 and MMP-9 after 3 hours ( Figure 7A ,B). LY294002 negated EP4 agonist-induced MMP-2 mRNA expression ( Figure 7C ).
YM58483 and U0126 also negated it. Similarly, these inhibitors negated EP4 agonist-induced MMP-9 mRNA expression ( Figure 7D ).
Gelatin zymography showed that PGE 2 increased the activation of MMP-2 and MMP-9, and the synthesis of pro-MMP-2 and pro-MMP-9. ONO-AE3-208 negated PGE 2 -induced MMP-2 and MMP-9 expression ( Figure 7E ). Taken together, we propose the mechanism of migration of EP4 in oral cancer cells ( Figure 7F ).
| D ISCUSS I ON
Prostaglandin E 2 exerts its diverse effects through four GPCR (EP1-4). In general, EP1 activation is associated with intracellular Ca 2+ elevation, mediated by phospholipase C (PLC) and IP 3 . 6 EP2 and EP4
receptors are known to couple to Gs and mediate the activation of PKA through cAMP. 6 Along with PKA, PI3K is also a major downstream target of EP4. 5 We identified that EP4 regulated cell migration through PI3K signaling and ERK signaling in oral cancer cells.
Fujino et al noted that PGE 2 stimulation of HEK cells stably expressing EP4 receptors caused ERK phosphorylation by a PI3K-dependent mechanism. 29 Ma et al reported that the EP4 receptor mediates ERK activation, resulting in cell migration of breast cancer. 47 Yang et al showed that selective antagonism of EP4 receptor signaling results in profound reduction in lung and colon cancer metastasis. 33 They also reported that the EP4 antagonist ONO-AE3-208 inhibited the phosphorylation of PBK/Akt, the downstream effector of PI3K, in Orai1 physically interacted with the N and C termini of TRPC3 and TRPC6. 48 They also showed that Orai1 and TRPC proteins colocalized and formed complexes that participate in Ca 2+ entry with or without activation of store depletion. 49 Ong and Ambudkar showed that Orai1 is a critical component of the active TRPC1 channelosome and that Orai1 determines the activation of TRPC1 following depletion of ER-Ca 2+ stores. 12 Conversely, in the current study, we showed that knockdown of STIM1 did not negate EP4-agonist-induced Ca
2+
influx. Furthermore, we confirmed that EP4 formed complexes with both Orai1 and TRPC1 that participate in Ca 2+ influx. More interestingly, nevertheless, the EP4 receptor is coupled to Gα and Gαi, EP4 induced Ca 2+ influx from the extracellular space. Regarding the mechanism of SOCE, it is well known that activation of GPCR (Gq) or immunoreceptors such as T-cell, B-cell and Fc receptors results in the production of IP 3 that binds to the IP 3 receptor located in the membrane of the ER, which is a Ca 2+ -permeable ion channel and F I G U R E 6 EP4 signaling regulated ERK phosphorylation through Orai1. A, Representative images of ERK phosphorylation are shown. Densitometric analyses of western blot show that phosphorylation of ERK was increased by EP4 agonist after 6 and 12 h (*P < .05, n = 4). B, Densitometric analyses of western blot show that LY294002 negated EP4 agonist-induced phosphorylation of ERK, not PKI-(14-22)-amide (*P < .05, n = 4). C and D, Densitometric analysis of western blots confirmed that ERK phosphorylation induced by EP4 agonists was not caused by Orai1 ablation of HSC-3 (*P < .05, n = 4). E, EP4 agonist ONO-AE1-437 increased the expression of calpain and cleaved α-spectrin in a time-dependent way. Densitometric analyses (bar graph) of western blots show the expression of calpain and cleaved α-spectrin (*P < .05, **P < .01, n = 4)
mediates the release of Ca 2+ from the ER. 50 The resulting decrease in human clinicopathological examination of oral squamous cell carcinoma was significantly more highly expressed than in normal oral tissue. 55 Therefore, we assumed that PGE 2 /EP4 signaling was highly upregulated and promoted tumor progression in oral cancer cells.
As far as we know, the novelty of the present study is that GPCR-like EP4, which is coupled to Gα and Gαi, induced Ca F I G U R E 7 EP4 signaling increased MMP-2 and MMP-9 gene expression and activation. A and B, Quantitative RT-PCR shows that the EP4 agonist increased mRNA of MMP-2 and MMP-9 over 3 and 6 h (*P < .05, ***P < .001, n = 4). C and D, Quantitative RT-PCR shows that LY294002, YM58483 and U0126 negated EP4 agonist-induced MMP-2 (left) and MMP-9 activation (right) (*P < .05, **P < .01, ***P < .001, n = 4). E, Gelatin zymography shows that PGE 2 significantly increased MMP-2 and MMP-9 activity, and the synthesis of pro-MMP-2 and pro-MMP-9 after 24 h (**P < .01, n = 4). EP4 antagonist ONO-AE3-208 negated PGE 2 -induced MMP-2 and MMP-9 activation. F, Proposed mechanism of EP4 signaling-mediated cell migration in oral cancer. EP4 stimulated by prostaglandin E (PGE) 2 activated PI3K and then induced Ca 2+ influx from the extracellular space through Orai1, resulting in ERK phosphorylation and the promotion of cell migration in oral cancer cells. EP4 stimulated Orai1, which formed a complex through PI3K. Ca 2+ then flowed into the cell from outside the cell through Orai1.
The secondary messenger Ca 2+ phosphorylated ERK and activated MMP. Meanwhile, Ca 2+ increased the expression of calpain, which is a Ca 2+ -dependent enzyme, and increased the cleavage of α-spectrin, a target enzyme of calpain. As a result, EP4 promoted cell migration in oral cancer cells. TRPC1, transient receptor potential canonical 1
